Morphosys moves closer to getting first antibody drug on market
FRANKFURT German biotech Morphosys moved a step closer to getting its first antibody drug onto the market as its licensee, Johnson Johnson unit Jenssen, reported positive results from a phase 3 study of psoriasis drug guselkumab.